Blood cancers

Treatment for relapsed or refractory Hodgkin lymphoma added to PBS

Brentuximab vedotin (Adcetris®) has been listed on the PBS for the treatment of patients with relapsed or refractory Hodgkin lymphoma. From 1st April the antibody-drug conjugate will be available to patients who: have relapsed or were refractory after having undergone an autologous stem-cell-transplantation (ASCT); or have relapsed or were refractory after at least two prior treatments and are ...

Already a member?

Login to keep reading.

© 2021 the limbic